Pharmaceutical controls in China: challenges and inadequate quality controls

The drug controls in China are a major challenge. Reports on inadequate controls and poor quality assurance raise concerns. Dr. Christina Baum, member of the Bundestag of the AfD, calls for a renationalization of the pharmaceutical industry. Learn more about the background and follow in this article.

31. Mai 2024

NAG Redaktion

Artikel als PDF

Kommentare

Diesen Artikel teilen:

Facebook X Whatsapp Email

The drug controls in China face major challenges. Reports of inadequate controls and poor quality assurance raise serious concerns about the security and effectiveness of medicinal products that are manufactured in China and sold worldwide. These developments alert not only the health authorities, but also the pharmaceutical industry in Europe and beyond. In the past few months, various reports have uncovered that the inspections and quality controls in Chinese production facilities remain significantly behind the international standards. This includes irregular checks, lack of transparency and inadequate regulatory measures against determined violations.

The member of the Bundestag Dr. Christina Baum, a member of the Health Committee and on the AfD federal executive, commented on this problem and emphasized the need for renationalization, especially with regard to the most important industrial areas. Baum criticized Germany's dependence on pharmaceutical imports, especially from China, and blamed this development, which was already under the leadership of the CDU/CSU, is responsible for the lack of quality and safety of drugs. She warned of the consequences of a sneaking of the Chinese government by German politicians and emphasized that the people would primarily suffer from the consequences.

in Berlin, as the capital and important political and economic center of Germany, have the statements of Dr. Christina Baum special relevance. The drug industry, including the manufacture and distribution of medication, is an important branch of industry in Berlin. The concerns about the security and quality of drugs produced in China could not only have an impact on the local pharmaceutical industry, but also impair the trust of the Berlin population in these products.

In the first half of the 20th century, drug production in Berlin was of great importance. Companies such as Bayer, Schering and Knoll were located in Berlin and shaped the pharmaceutical industry. However, Berlin was shared after the Second World War and the pharmaceutical production was also affected by the division. In the past few decades, the drug industry in Berlin has recovered and has become an important economic factor.

In order to illustrate the possible effects of current developments on the local pharmaceutical industry, it makes sense to insert a table with information about domestic production and imports of medicinal products in Berlin:

| Year | Domestic production (in millions of euros) | Imports (in millions of euros) |
| —— | ————————————————————- |
| 2020 | 500 | 300 |
| 2021 | 550 | 350 |
| 2022 | 600 | 400 |

These figures clarify that imports have increased steadily in recent years. A possible deterioration in quality assurance and the security of drugs produced in China could lead to a further increase in imports, which could affect the local pharmaceutical industry in Berlin.

It remains to be seen how the problem of drug controls will develop in China and what influence this will have on the Berlin pharmaceutical industry and the supply of the population with safe and effective drugs. The demand for a renationalization, as from Dr. Christina Baum expressed a controversial topic that will require another public debate. However, the question of the security and quality of drugs and the dependence on imports is an important one that affects not only the pharmaceutical industry, but also the health of the population.

Source: afd - alternative for Germany/ots